EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The adipo-hepatic axis: Molecular convergence of obesity and metabolic dysfunction-associated steatotic liver disease

Aayed R. Alqahtani, Hanan Abdurabu

Saudi Journal of Obesity · 2023-01 · 11 (1) · 1-11

DOI: 10.4103/sjo.sjo_1_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Journal of Obesity, online erschienen am 16.11.2026. Verfasst von Aayed R. Alqahtani und 1 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2023, for the name nonalcoholic fatty liver disease was changed to reflect the strong association that it has with metabolic dysfunction and is called now metabolic dysfunction-associated steatotic liver disease (MASLD). Around one-third of the global adult population is estimated to have MASLD. It has become a leading disease of the liver associated with systemic obesity and insulin resistance. In this article, hepatic lipid accumulation is addressed with the association of obesity and the subsequent inflammatory and fibrotic responses. We analyze the effect of visceral fat and the subsequent hypertrophy of adipose tissue in conjunction with obesity-related inflammation and the upregulation of leptin and resistin (and other inflammatory cytokines) on the impairment of insulin signaling pathways. This also alters macromolecular interactions and pathways in the liver. Unsurprisingly, insulin resistance in the liver allows the uncontrolled adipose lipolysis to further heighten the levels of insulin in blood circulation. This activates and supports the increase of lipogenesis via sterol regulatory element-binding protein-1c in conjunction with cellular retinol-binding proteins in the liver. We address the role of the PNPLA3 gene and the transmembrane 6 superfamily member 2, HSD17B13 variants, and dysbiosis in the gut microbiome and its influence on steatosis and hepatofibrosis. We elaborate on the intersections of the NLRP3 inflammasome, ferroptosis and mitochondrial dysfunction, oxidative stress and hepatic stellate cell transformation in the pathogenesis of steatosis, and liver fibrosis that progresses to hepatocellular cancer. This review also includes a discussion on the emerging drug targets for the treatment of MASLD, including the incretin mimetics, bariatric surgery, and also the new thyroid hormone receptor beta-modulators (resmetirom). For the improvement of specialized preventive and treatment procedures regarding obesity-induced liver disease, developing an accurate understanding of this adipo-hepatic molecular continuum is crucial.

Zitieren

APA

Alqahtani, A. R., & Abdurabu, H. (2023). The adipo-hepatic axis: Molecular convergence of obesity and metabolic dysfunction-associated steatotic liver disease. Saudi Journal of Obesity, 11(1), 1-11. https://doi.org/10.4103/sjo.sjo_1_26

Vancouver

Alqahtani AR, Abdurabu H. The adipo-hepatic axis: Molecular convergence of obesity and metabolic dysfunction-associated steatotic liver disease. Saudi Journal of Obesity. 2023;11(1):1-11. doi:10.4103/sjo.sjo_1_26

BibTeX
@article{Alqahtani2023,
  author = {Alqahtani, Aayed R. and Abdurabu, Hanan},
  title = {The adipo-hepatic axis: Molecular convergence of obesity and metabolic dysfunction-associated steatotic liver disease},
  journal = {Saudi Journal of Obesity},
  year = {2023},
  volume = {11},
  number = {1},
  pages = {1--11},
  doi = {10.4103/sjo.sjo_1_26}
}
Kostenlos starten →